<DOC>
	<DOCNO>NCT02987634</DOCNO>
	<brief_summary>Izun Pharmaceuticals show PeriActive , oral rinse contain extract Sambucus nigra , Echinacea purpurea , Centella asiatica significantly reduce gingival inflammation experimental gingivitis model phase II study , well numerous clinical trial . The product individual component show safe . Based favorable result , Izun seek demonstrate combine anti-bacterial/anti-inflammatory rinse potentially enhance soft tissue heal reduce localize inflammation follow dental implant surgery equal , good , chlorhexidine rinse , few side effect .</brief_summary>
	<brief_title>Evaluation Comparison Efficacy PeriActive Mouthwash Chlorhexidine 0.12 % Mouth Rinse</brief_title>
	<detailed_description>This randomized phase IV control trial two parallel arm : ( 1 ) PeriActive rinse ( 2 ) Chlorhexidine 0.12 % rinse . Subjects randomize one two treatment group time implant surgery . An alternate 1:1 randomization scheme use , first patient receive Chlorhexidine , second patient receive PeriActive , third patient receive Chlorhexidine forth . Implant surgery require incision tissue reflection . Implant ( ) place bone level ( +/- 2 mm ) . The abutment place transgingival least 2 mm soft tissue level . Tissues suture 6-0 ePTFE ( Goretex ) suture , need . Antibiotics prescribe 7 day follow surgery . In addition , end surgical visit , patient issue two bottle assign rinse use twice day . Details Study Visits Screening/Visit 1 - Day 0 Following signing informed consent form , adult male female subject age ≥18 year screen study eligibility assessment inclusion exclusion criterion . Screening procedure include collection demographic data medical history . Eligible subject undergo implant surgery , relevant index measure . Subjects instructed rinse relevant oral rinse give two bottle remainder study . Visits 2 3 - 2 4 week ( ± 3 day ) post-surgery , respectively At visit 2 , suture remove light curetting site ( need ) perform , follow evaluation Gingival Index ( GI ; modify incision ) , Plaque Index ( PI ) compliance protocol . At visit 3 , clinical index compliance protocol evaluate .</detailed_description>
	<mesh_term>Periodontal Diseases</mesh_term>
	<mesh_term>Gingival Diseases</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<criteria>1 . Subjects must adult male female age 18 year . 2 . Subjects must able willing follow study procedure instruction . 3 . Subjects must present need implant surgery would necessitate surgical incision ( flap elevation ) transgingival implant healing cap , available followup visit able follow rinse protocol instruction . 1 . Subjects exhibit gross oral pathology severe gingival inflammation time surgery project surgical site . 2 . Subjects chronically treat ( i.e. , ≥ two week ) antiinflammatory medication ( steroid nonsteroidal antiinflammatory drug ) medication know affect gingival tissue status ( e.g. , phenytoin , cyclosporine ) within one month screen examination . Prophylactic use aspirin ( 81 mg daily ) Plavix use cardiovascular indication permit ( note insert patient 's documentation ) therapeutic treatment modification jurisdiction treat dentist . All medication chronic medical condition initiate least three month prior enrollment . 3 . Subjects active infectious disease hepatitis , human immunodeficiency virus ( HIV ) tuberculosis 4 . Subjects Types I II diabetes , thyroid disease cancer chemotherapy 5 . Subjects report allergy constituent rinse 6 . Female subject report pregnant lactate 7 . Subjects clinically significant laboratory result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>gingivitis</keyword>
	<keyword>dental implant</keyword>
	<keyword>mouthwash</keyword>
</DOC>